IndraLab

Statements

Pazopanib inhibits RIPK1. 5 / 5
2 | 1 2
reach
"Furthermore, ponatinib and pazopanib are expected to suppress the activity of receptor-interacting serine/threonine protein kinase 1 (RIPK1), a SARS-CoV-2 NSP12 interactor linked to apoptosis, necroptosis, and inflammatory processes [167]."
36252792
reach
"Interestingly, some US Food and Drug Administration-approved anticancer drugs, including ponatinib and pazopanib, can inhibit RIPK1; these drugs would be better prospects in further clinical studies (Fauster et al., 2015)."
34594225
tas
No evidence text available
22037378
eidos
"In addition , the activity of RIPK1 , an NSP12 interactor which is associated with apoptosis , necroptosis , and inflammatory pathways , is predicted to be inhibited by ponatinib and pazopanib ."
32444466
tas
No evidence text available
18183025